TBX-2400
TBX-2400: A NEW CLASS OF CELL THERAPY
TBX-2400 Overview
-
TBX-2400 is an allogeneic stem cell product being developed to improve bone marrow transplants.
-
The U.S. FDA has approved TBX-2400’s IND.
-
Treatment includes the infusion of donor hematopoietic stem cells treated with TBX-4000.
Key Milestones
-
US Orphan Drug Designation.
-
US Rare Pediatric Drug Designation.
-
EMA Orphan Drug Designation.
-
EMA Advanced Therapy Medicinal Product Designation.
IMPROVING BONE MARROW TRANSPLANTS
Composed of donor hematopoietic stem cells treated ex vivo for 1 hour with TBX-4000.
1. Blood Collection: blood is drawn from the donor in a hospital or clinic in an outpatient setting.
2. Processing: the bone marrow stem cells are separated and treated with Taiga's TBX-4000 protein.
3. Treatment: the treated cells are then given to the patient.
TBX-2400: BETTER, FASTER, AFFORDABLE
Issues with today's allogenetic BMTs
TAIGA's TBX-2400
